SSY Group Limited (HKG:2005)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.400
+0.010 (0.42%)
At close: Mar 27, 2026
Market Cap6.96B -27.5%
Revenue (ttm)4.17B -27.8%
Net Income470.64M -55.6%
EPS0.16 -55.2%
Shares Out2.90B
PE Ratio14.95
Forward PE9.23
Dividend0.15 (6.04%)
Ex-Dividend DateMay 20, 2026
Volume9,002,000
Average Volume14,300,841
Open2.380
Previous Close2.390
Day's Range2.370 - 2.430
52-Week Range2.350 - 3.470
Beta0.49
RSI35.03
Earnings DateMar 27, 2026

About SSY Group

SSY Group Limited, an investment holding company, researches, develops, manufactures, trades in, and sells various pharmaceutical products to hospitals and distributors in the People’s Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC and upright soft bag, PP plastic bottle, and glass bottle infusion solutions, as well as ampoule injections. It also provides small volume injections, oral preparations, Chinese medicine preparations, and biological preparations, as well as bulk pharmaceuti... [Read more]

Sector Healthcare
Founded 1999
Employees 5,700
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2005
Full Company Profile

Financial Performance

In 2025, SSY Group's revenue was 4.17 billion, a decrease of -27.85% compared to the previous year's 5.77 billion. Earnings were 470.64 million, a decrease of -55.65%.

Financial Statements

News

SSY Group FY25 Profit Drops On Weak Revenues; Cuts Dividend- Update

(RTTNews) - SSY Group Ltd., (LJUIF, 2005.HK), a Chinese pharmaceutical manufacturer, reported Friday lower profit in fiscal 2025 with weak revenues. The company also announced a cut in dividend.

2 days ago - Nasdaq

SSY Group 9-months Profit Falls

(RTTNews) - SSY Group Ltd., (LJUIF,2005.HK) an investment holding company, on Tuesday reported a sharp decline in profit for the nine-month period, ended September 30, as the results were hurt by weak...

5 months ago - Nasdaq

SSY Group Secures Approval For Levamlodipine Besilate Tablets For Hypertension Treatment In China

(RTTNews) - SSY Group Limited announced that it has received approvals for the production and registration of Levamlodipine Besilate Tablets (5mg and 2.5mg) from the National Medical Products Administ...

5 months ago - Nasdaq